We dive into the future of the farm and where technology is taking it next, from agricultural drones to crop biologicals.
The Series F round brings Benchling's total funding to $412M. Here are the top-line bullets you need to know.
Funding to psychedelics startups is on the rise. We discuss the sector’s market drivers, emerging themes, and key implications.
The Series B round brings Catalog's total funding to $54.2M. Here are the top-line bullets you need to know.
Big tech is coming for pharma. We analyze Amazon, Microsoft, Apple, and Google’s strategies and priorities across the pharmaceutical value chain.
Allozymes plans to use the funds to build out its enzyme development platform. Here are the top-line bullets you need to know.
Benchling attained unicorn status at a $4B valuation amid its IPO preparations. Here are the top-line bullets you need to know.
The temperature requirements for Covid-19 vaccines have focused attention on the cold chain, with nearly 6x more earnings calls mentions vs. last year. Here are the top-line bullets you need to know.
For temperature-sensitive products from food to vaccines, cold chain technology enables temperature control and monitoring throughout the supply chain.
AI in healthcare has gained significant traction during the pandemic, from combing scientific papers on coronaviruses to searching CT scans for Covid-19 symptoms. We look at where AI will have a lasting impact on the industry.
From opening your smartphone to unlocking your car to paying for groceries, biometrics is becoming a go-to method for identification.
Move fast and break things — it's the startup ethos. Here's what happens when it goes wrong.
CB Insights produces healthcare research across digital health, pharma, medical devices, biotech, and much more. Below you can find our most popular research organized by theme and function.
Also covered are challenger banks, high tech agriculture, and data centers at the edge.
The head of computing at Google's anti-aging research firm envisions data as a key tool to expand personalized medicine — and maybe eventually extend human life.
While deal flow remains even, a $1B+ raise by Roivant Sciences is boosting funding in the European pharma sector to record highs.
Study participants are swallowing pills containing gene-modified E. coli bacteria designed to absorb excess ammonia in the body.
Healthcare is changing around the world. The very definition of medicine is now up for debate. Across digital health, biotechnology, and the medical device sector, startups are finally bringing medicine into the 21st century. In this report we take a look at cutting edge developments in healthcare, and the startups behind them that are just beginning to impact the world.
Scientists screened a library of 100 million antibodies to find several that offer an easier way to reprogram adult cells into stem cells.
This dime-sized chip transforms cells from one type to another with a small electrical pulse – creating a non-invasive, instantaneous way to repair injured tissue.
Exposure to indole compounds produced by E coli bacteria helped certain animals stay active and mobile at advanced ages – paving the way for new drugs that could help humans live well into old age.
Spiders that ingested graphene and carbon nanotubes produced silk that was tougher than Kevlar – potentially paving the way for a new class of high-performing bio-enhanced materials.
Invasive bone grafts may be on the way out: A new gene therapy procedure using gas-filled microbubbles healed fractures in just 8 weeks.
We used the CB Insights database to identify companies that are using AI to expedite various stages of the clinical trial process, from drug formulation to patient recruitment.